What kind of drug is Tucatinib?

Release date: 2026-05-26 14:53:59     Recommended: 15

What kind of drug is Tucatinib?

Tucatinib is a prescription medicine used to treat breast cancer, with the active ingredient being tucatinib. It belongs to a class of drugs called "protein kinase inhibitors," which precisely interfere with signaling pathways inside cancer cells, thereby effectively preventing the growth and spread of specific types of cancer cells. Tucatinib is typically provided as film-coated tablets in two strengths: 50 mg and 150 mg, allowing doctors to adjust the dosage based on the patient's condition. It is not used alone but in combination with two other anticancer drugs—trastuzumab and capecitabine. Patients should obtain the separate prescribing information for these two drugs from their doctor to fully understand the entire treatment regimen.

Which breast cancer patients is Tucatinib suitable for?

This drug is specifically used for adult breast cancer patients who must meet all of the following criteria: First, the patient's cancer cells have a target on their surface called "human epidermal growth factor receptor 2," medically known as HER2-positive breast cancer. Second, the cancer has spread beyond the original tumor site to other parts of the body (such as the brain), or cannot be completely removed by surgery due to its location or size. Additionally, patients should have previously received certain other standard treatments for breast cancer. For patients who meet these criteria, doctors may consider the tucatinib combination therapy in order to more effectively control disease progression.

How does Tucatinib work against cancer?

Cancer cell growth often depends on specific signaling stimuli. In HER2-positive breast cancer, HER2 receptors on the surface of cancer cells are abnormally active, continuously sending erroneous "proliferate and survive" signals inside the cells. The core mechanism of tucatinib is to precisely block these HER2 receptors. It can be thought of as a specialized "key" that plugs into the "lock" of the HER2 receptor, preventing the cancer-causing signals from being transmitted. Once the signal is blocked, the growth rate of cancer cells slows down, or even stops completely; ideally, some cancer cells may die. Thus, tucatinib effectively inhibits tumor progression through this targeted blocking strategy.